Using microvascular endothelial cells, lung cancer derived fibroblasts, and NSCLC tumor cells in the presence of patient tumor-derived hemodynamic flow and transport we demonstrate that the TMES predicts drug response to EGFR inhibitors, a standard of care for EGFR mutant NSCLC. The gene discussed is EGFR; the disease is lung carcinoma.